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To address the global burden of sickle cell disease and the need for novel therapies, the
American Society of Hematology partnered with the US Food and Drug Administration to
engage the work of 7 panels of clinicians, investigators, and patients to develop consensus
recommendations for clinical trial end points. The panels conducted their work through
literature reviews, assessment of available evidence, and expert judgment focusing on end
points related topatient-reported outcome, pain (non–patient-reported outcomes), the brain,
end-organ considerations, biomarkers, measurement of cure, and low-resource settings.
This article presents the ﬁndings and recommendations of the end-organ considerations,
measurement of cure, and low-resource settings panels as well as relevant ﬁndings and
recommendations from the biomarkers panel.
Introduction
Sickle cell disease (SCD) is the most common inherited red blood cell (RBC) disorder in the United
States, affecting 70 000 to 100000 Americans.1 Although the molecular basis of SCD was established
decades ago, it has been challenging to translate this knowledge into the development of novel
therapies. To improve therapeutic options, clinical trials employing carefully defined and appropriately
chosen end points are needed that can capture patient benefit. These end points will enable scientific
advancement, improvements in patient care, and product approvals.
Submitted 23 August 2019; accepted 7 October 2019. DOI 10.1182/
bloodadvances.2019000883.
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As part of a multifaceted initiative addressing the global burden of
SCD, the American Society of Hematology (ASH) partnered with
the US Food and Drug Administration (FDA) to engage the work
of 7 panels of clinicians, investigators, and patients to develop
consensus recommendations for SCD end points. The panels
conducted their work through literature reviews, assessment of
available evidence, and expert judgment focusing on end points
related to patient-reported outcome (PROs), pain (non-PROs),
the brain, end-organ considerations, biomarkers, measurement
of cure, and those appropriate for low-resource settings. In
conducting their reviews, the panels considered a broad range
of end point definitions, including biomarkers as well as fully
qualified clinical end points denoting clinical benefit that could
be used for a regulatory approval. Clinical benefit was defined
as “what a patient would want from a therapeutic procedure,
such as improved survival, symptom improvement, or decreased
risk of developing disease or morbidity (eg, stroke).” End points
should reflect patient desires and integrate objective measure-
ments to assess disease severity and progression. Ideally, an
end point should be easy to measure accurately at low cost and
at low burden for the patient and research team. Further, it
should be interpretable and clinically relevant and available to
be measured in all patients in a study facilitating complete data
collection.
The results of the panels’ work were presented and discussed at
a public workshop in October 2018 attended by 188 in-person
and 750 viewing online via live stream from 20 countries. Intra- and
interpanel discussions as well as exchanges with attendees further
informed the process. This article presents the findings and recom-
mendations of the end-organ considerations, measurement of cure,
and low-resource settings panels as well as relevant findings and
recommendations from the biomarkers panel. Findings and recom-
mendations from the other panels are reported separately (see
accompanying article by Farrell et al2).
The workshop presenters noted significant differences between
definition of end points and biomarkers applied as end points.
Building off the BEST (Biomarkers, End pointS, and other Tools)
resource,3 the panels concurred with the definition of a biomarker
as a defined characteristic measured as an indicator of normal
biological or pathogenic processes or responses to an exposure
or intervention. A biomarker is not an “end point” that evaluates
how an individual feels, functions, or survives. A full biomarker
description includes the biomarker name, the source/matrix, the
measurable characteristics, and the analytic method used to
measure the biomarker. Biomarkers can be further classified as
those that, for example, stratify susceptibility/risk biomarker,
diagnosis, disease/product monitoring, and prognosis. While
many biomarkers associated with SCD complications represent
findings from single and small study populations, the authors
attempted to discriminate those biomarkers that are well estab-
lished from those that are used for research purposes. Specifically,
in to evaluate a biomarker in SCD, several pieces of information
were evaluated and varied for each biomarker, including but not
limited to evidence (quantity and quality of) on the measurability,
sensitivity, specificity, reliability, and laboratory-to-laboratory
reproducibility. These characteristics are defined as analytical
validation for a given biomarker by the BEST document and
helped guide committee views on defining the presence and
value of biomarkers in SCD.
End-organ diseases: renal and
cardiopulmonary end points in SCD
Adult patients with SCD have evidence of end-organ disease, and
patients with multiple end-organ complications are at high risk
for mortality.4-9 Conducting clinical trials aimed at preventing
end-organ damage is vital to reduce morbidity and mortality. The
end-organ considerations panel focused on renal and cardio-
pulmonary end points (Tables 1 and 2) while recognizing that
other complications exist. Relevant recommendations of the
biomarkers panel are also included here.
Renal end points
SCD patients face multiple renal morbidities, including chronic
kidney disease (CKD), hypertension, hyposthenia, and acute
kidney injury (see Table 1 for a summary).
Albuminuria and CKD The prevalence of albuminuria increases
from early adolescence into adulthood.10-12 Risk factors for the
development of albuminuria include increasing age, hyperfiltra-
tion, elevated blood pressure, leukocytosis, anemia, hemoglo-
binuria and increased hemolytic markers.10,11,13-15 Moderate
and severe albuminuria are highly prevalent, and understanding
the natural history of progression, including the role of genetic
variants (eg, APOL116-18), will facilitate targeting the prevention
or treatment of albuminuria. Therefore, therapeutic development
should use biomarkers and end points that capture progression
to end-stage renal disease.
Preclinical data suggest that moderate albuminuria may be due to
competitive inhibition of albumin uptake in the proximal tubular due
to underlying hemolysis rather than progressive glomerular injury.19
Novel agents preventing hemolysis may improve mild albuminuria
due to tubular reuptake of albumin rather than improving glomerular
filtration. Therefore, higher importance should be placed on clinical
trial end points for severe albuminuria as compared with moderate
albuminuria. Clinical trials should consider the impact of genetic
variants on progression to albuminuria possibly stratifying patients
based on known risk factors for disease.
The Kidney Disease Improving Global Outcomes (KDIGO) 2012
Clinical Practice Guidelines for the Evaluation and Management of
Chronic Kidney Disease define CKD by 3 albuminuria categories:
normal to mildly increased (,30 mg/g), moderately increased
(30-300 mg/g), and severely increased (.300 mg/g). KDIGO
guidelines or similar appropriate clinical guidelines should be
used for defining albuminuria end points in SCD clinical trials.20
Ideally, an albumin creatinine ratio should be used to quantitate
albuminuria, but a urine protein creatinine ratio is also accept-
able. During eligibility screening, an early-morning urine sample
should be used to differentiate postural or orthostatic proteinuria
from recumbent proteinuria. As an alternative, an untimed albuminuria
sample can be used but must be confirmed with either a positive early
morning void result or a repeat untimed urine sample. During a trial,
early morning samples should be used for albuminuria end points
rather than untimed urine samples if feasible.
Assessing albuminuria by use of a 30% decrease in albumin
creatinine ratio is recommended, although lower or higher percent
decreases (10% to 50%) have been used. In sum, prevention of
severe albuminuria and development of end-stage renal disease
represents a benefit. Natural history studies are needed to understand
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disease progression in patients with low to moderate albuminuria (near
30 mg/g albumin creatinine ratio) prior to considering improvement
in low to moderate albuminuria as an end point.
CKD and GFR Pediatric patients develop an elevated glomerular
filtration rate (GFR) in early childhood (hyperfiltration) that persists
during adolescence and young adulthood.21-23 In adulthood,
patients begin to experience an annual GFR decline.24,25
Patients who progress to end-stage renal disease suffer in-
creased mortality rates and may be less likely to receive a renal
transplant.26-28
Recent murine and human SCD studies suggests that hyper-
filtration precedes the development of albuminuria.14,29 Pro-
spective longitudinal studies must further define hyperfiltration
and determine the temporal association of hyperfiltration with
renal pathology in adults prior to recommending hyperfiltration
prevention as a pediatric trial end point. If hyperfiltration is pathologic,
preventing hyperfiltration development in the pediatric population is
an important end point.
Although direct measures of GFR are preferred, the practicability of
direct measurements can challenge trial feasibility. In these cases,
Table 1. End points for renal complications associated with SCD
Condition End point Test Outcome/outcome measure Type of end point Ages
CKD, albuminuria Albuminuria or proteinuria First morning void or 2 consecutive
untimed albumin/creatinine ratio
or protein/creatine ratio




CKD, GFR Renal replacement therapy Initiation of renal replacement
therapy (may differ based on
clinical practice)
Percentage of patients who require
initiation of renal replacement
therapy
Direct All age groups
CKD, GFR GFR Measured GFR and estimated
GFR
Percentage of patients who progress
in stage of CKD or percentage of
decline in GFR
Surrogate Adults
Hypertension Cardiovascular end point Clinically defined Number of patients who develop
stroke, myocardial infarction, death
Direct All age groups
Hypertension Systolic or diastolic blood pressure;
pediatric studies should consider
use of ambulatory blood pressure
monitoring
Blood pressure measurement Change in systolic or diastolic blood
pressure (5 mm Hg)
Future All age groups
Hyposthenuria Urine concentration availability Water deprivation test; not .10 h
in children; meaningful tests are
those concentrating urine
.500 mOsm/kg H2O
Percentage of patients with




Kidney injury Acute kidney injury defined by serum
creatinine or urine output;
biomarker of kidney injury
Serum creatinine or urine output;
novel biomarkers of kidney
injury (eg, NGAL, KIM-1)
Percentage of patients who develop
acute kidney injury; reduction in
urine biomarkers (25% change)
Future All age groups
KIM-1, kidney injury molecule 1; NGAL, neutrophil gelatinase-associated lipoprotein.
Table 2. End points for cardiovascular complications associated with SCD
Condition End point Test Outcome/outcome measure Type of end point Ages





PH and risk of death TRV Doppler echocardiography TRV $3.0 m/s or TRV $2.5 m/s and
NT-pro-BNP level .160 pg/mL
Surrogate Adults
PH and risk of death Composite model Doppler echocardiography,
NT-pro-BNP, and 6-min walk test
TRV.2.5 m/s, NT-pro-BNP level$160
pg/mL, and 6-min walk test ,330 m
Surrogate Adults
Diastolic dysfunction E/e9 and E/A; myocardial fibrosis Echocardiogram; cardiac MRI Percent improvement toward normal Future All age groups
Functional exercise capacity Walk distance 6-min walk test Change in distance walked (30-40 m) Direct Adults
ACS Incidence using an accepted
definition; progression using an
accepted definition
Clinically defined Percentage of patients who develop
ACS; percent of patients that
clinically worsen; respiratory support,
O2 requirement, transfusion therapy
Direct All age groups
Asthma Development of ACS, pain event, or
asthma exacerbation
Clinically defined Time to event in incidence of ACS, pain
crisis, or use of rescue inhaler
(number of events/days using rescue
inhaler) low FEV1 at baseline
Direct All age groups
Indirect
Thromboembolism Pulmonary embolism, VTE Clinically defined thrombus Percentage of patients with either
pulmonary or VTE
Direct All age groups
FEV1, forced expiratory volume in 1 second; MRI, magnetic resonance imaging.
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studies should use an estimated GFR equation (serum creatinine
and/or cystatin) with the least bias based on the current literature
but future research is needed to determine a sickle cell–specific
estimated GFR or more feasible measured GFR.21,30,31 For
clinical trials evaluating GFR decline, the end point could be
either progression in CKD stages or percentage GFR decline.
Future research is needed to improve our understanding of the
natural history of annual decline in GFR on clinical outcomes.
Caution is needed in enrolling patients with hyperfiltration and
using the percent decrease in GFR as an end point, as these
patients may return to a normal filtration if their overall SCD
improves, which would not indicate disease progression.
For patients with CKD stages 4 or 5, trials using initiation of renal
replacement therapy is a direct end point. For patients with CKD
stages 1 to 3, trials using decline in stage or percent decline in GFR
should be considered.
Hypertension Guidelines have been developed to diagnose
and treat hypertension in the adult and pediatric populations.32,33
Although patients may have lower blood pressure than the general
population, hypertension in these patients is associated with signif-
icant morbidity and mortality.34-38 Accepted end point measures of
antihypertensive intervention can be used in clinical trials including
clinical cardiovascular end points (death, myocardial infarction,
and stroke) or change in systolic or diastolic blood pressure.
The methodology for obtaining blood pressure in a clinical trial
should follow current guideline statement recommendations.32,33
Using 24-hour ambulatory blood pressure monitoring can allow
for a more accurate assessment of hypertension and is superior
to office assessments to predict long-term cardiovascular disease
outcomes.32,39
Hyposthenuria Loss of renal concentrating ability (hyposthenuria)
occurs early in life. Almost one-quarter of infants in the Baby
HUG trial were unable to concentrate their urine after modest
water deprivation.22,40 Because urine-concentrating defects
develop early in life, clinical trials aimed at reducing hyposthe-
nuria development should occur in children with this manifesta-
tion. Hyposthenuria should be viewed as a surrogate biomarker;
however, if future studies identify a link between hyposthenuria
and kidney disease, hyposthenuria prevention could be considered
a direct end point.
Biomarkers of kidney injury Acute kidney injury has a bidirec-
tional association with CKD.41 Patients develop acute kidney injury
during a crisis.42-44 KDIGO defines acute kidney injury as an
increase in serum creatinine or a decrease in urine output. In
SCD, serum creatinine may underestimate a change in GFR and
urine output may be affected by hyposthenuria. Therefore, addi-
tional research in urine biomarkers of acute kidney injury are
warranted, such as N-acetyl-b-D-glucosaminidase,10 HMOX1
variants,45 uric acid,46 b2 microglobulin,47-50 soluble FMS-like
tyrosine kinase,51 kidney injury molecule 1,45,52,53 monocyte
chemoattractant protein,54 neutrophil gelatinase-associated
lipoprotein,45 transforming growth factor-b1,10,55 endothelin-1,56
and nephrin.29
Cardiopulmonary end points
Several direct end points involve cardiopulmonary complications
that occur commonly in SCD, including pulmonary hypertension
(PH), defined by right heart catheterization (RHC) or estimated
from Doppler echocardiography, diastolic dysfunction, func-
tional exercise capacity, acute chest syndrome (ACS), asthma,
and thromboembolism (see Table 2 for a summary).
PH PH is newly defined hemodynamically as a mean pulmonary
artery pressure (mPAP) .20 mm Hg. Based on the prior definition
of mPAP$25 mm Hg, PH occurs in 6% to 11% of SCD adults and
carries with it a 40% 6-year mortality.57-59 Pulmonary arterial (PA)
hypertension (PAH) is also newly defined by a mPAP of .20 mm
Hg, with a PA wedge pressure of #15 mm Hg and a pulmonary
vascular resistance (PVR) of$3Wood units, indicating an increase
in the precapillary pulmonary pressures.60 However, an mPAP
$25 mm Hg threshold as abnormal is not based on experimental
data. The mean (standard deviation) mPAP in healthy patients is
14.0 (3.3) mm Hg.61 A mean PAP between 21 and 24 mm Hg has
been identified as associated with high risk of death and has now
been proposed to represent “mild” PH, likely significantly increasing
the prevalence of hemodynamic PH in the SCD population.62 In
patients with SCD, this pathophysiology is driven in large part by
the intravascular injurious effects of hemolysis.63 PAH leads to
progressive right heart failure and reduced exercise capacity.
Pulmonary venous hypertension is often due to increases in left-
sided filling pressures, related to systolic or, more commonly,
diastolic dysfunction of the left ventricle or left-sided valvular
disease. Both hemodynamic forms of PH are independent predictors
of death in the adult SCD population.59
Cardiopulmonary hemodynamic biomarkers as end points
RHC is the most accurate diagnostic test to establish PH. Hemody-
namic variables, including PA systolic and diastolic pressures, mean
PA pressures (mPAP), the transpulmonary gradient (TPG; which is
the mPAP–PA wedge pressure), and PVR directly correlate with
mortality risk in SCD.59
RHC hemodynamics have been used as clinical trial end points
for PAH medications in non-SCD populations, and reductions in
these hemodynamic end points could be employed. In non-SCD
PAH, the 2 hemodynamic variables with the greatest associated
mortality risk are an elevated mean right atrial pressure (RAP)
(.15-20 mm Hg) and a reduced cardiac index (#2.0 L/min/m2).64
RAP reduction to ,8 mm Hg and cardiac index increase to
.2.5 L/min/m2 after 6 months of macitentan treatment was
observed to increase survival in patients with non-SCD PAH.65
In SCD, hemodynamic variables, including PA systolic and diastolic
pressures, mPAP, and PVR, directly correlate with mortality risk.
Moreover, precapillary PH, as evidenced by an elevated TPG and an
elevated PA diastolic pressure to wedge pressure gradient, appears
to confer higher mortality risk than postcapillary PH.59 This suggests
that hemodynamic goals could be used as clinical trials end points.
It is important to remember that in SCD, some of these hemodynamic
threshold goals need modification, reflecting anemia-related con-
sequences such as elevated cardiac index at baseline, which results
in a lower “normal” PVR value. A value $160 dynes/s/cm25 or
2 Wood units has been proposed as abnormal for adult patients
with SCD.57
A 2017 report suggested a PVR of$160 dynes/s/cm25 or 2Wood
units was more specific for PAH than PH in SCD.57,65 With
adjustments, RAP, cardiac index, and PVR could serve as clinical
end points for PAH in SCD. Additional clinical end points such as
hospitalization related to PH and/or right heart failure, or initiation of
additional PAH medications or dose modification, could also be
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considered. Currently, our understanding of hemodynamics and
PH-associated mortality in SCD is limited to adults $18 years of
age. Clinical end points along with changes in cardiac index and
PVR could be considered direct hemodynamic end points, while
RAP (a reflection of right heart function) is a surrogate end point.
TRV and NT-pro-BNP levels RHC remains the gold standard
test for PH diagnosis. In settings where RHC may not be available,
or for initial screening of patients, the use of surrogate markers
for PH, including elevated tricuspid regurgitation velocity (TRV)
and N-terminal pro-brain natriuretic peptide (NT-pro-BNP)
levels, can be considered. Forty-five screening studies for PH
using Doppler echocardiographic determination of TRV values,
including .6000 patients, have been analyzed. The average
prevalence of elevated TRV $2.5 m/s in this meta-analysis was
21% (range, 17% to 26%) in children and 30% (range, 26% to
35%) in adults.66 A high TRV ($2.5 m/s) is associated with
a 30.4 m (range, 6.9-53.9) reduction in 6-minute walk distance and
a mortality hazard ratio of 4.9 (range, 2.4-9.7).66 In a large single-
institution cohort study, a TRV $2.5 m/s was associated with
a hazard ratio of death of 6.81 in multivariate analysis (P , .001).67
In this study, a value of 2.5 m/s was identified by receiver operator
analysis as the best cutoff value to predict mortality. Elevated TRV
values also identify patients at higher risk of having PH by RHC;
;40% of patients with a TRV value of 2.5 to 2.9 m/s have PH, while
75% of patients with a value $3.0 m/s have PH.59
The observational cohort of the Treatment of Pulmonary Hypertension
and Sickle Cell Disease with Sildenafil Therapy (Walk-PHaSST) study
followed 632 patients with SCD for 24 months.68 Sixty-four patients
(10.1%) had TRVmeasurements$3.0 m/s or higher, and 140 (22.2%)
had NT-pro-BNP measurements$160 pg/mL; 39 patients (6.2%) had
both TRV $3.0 m/s and NT-pro-BNP $160 pg/mL At 24 months,
the cumulative survival was 83% with TRV $3.0 m/s and 98% with
TRV ,3.0 m/s (P , .0001). The hazard ratios for death were
11.1 (95% confidence interval (CI), 4.1-30.1; P , .0001) for
TRV$ 3.0 m/s, 4.6 (95 %CI,1.8-11.3; P5 .001) for NT-proBNP$
160 pg/mL, and 14.9 (95% CI, 5.5-39.9; P , .0001) for both
TRV $3.0 m/s and NT-pro-BNP $160 pg/mL. Adjustment for
aspartate aminotransferase and creatinine had little effect on
the significance of the association between the combined TRV
and NT-proBNP variable and mortality.
This composite biomarker yields both a hazard ratio of 14.86 (95% CI,
5.5-39.9) for mortality60,68 and improved PPV for the PH diagnosis.58
While patients with severe renal disease were excluded during the
evaluation of association of the composite biomarker with PH, it has
a positive predictive value for PH of .60%.58 Therefore, the panel
suggests using a TRV $3.0 m/s alone or TRV value of 2.5 to
2.9 m/s in combination with a NT-pro-BNP level $160 pg/mL or
6-minute walk ,330 m to identify patients at high risk of PH or
death (excluding patients with severe renal disease). Reduction
of the composite biomarker, however, has not been closely evalu-
ated for predicting improved clinical outcome and is not generally
accepted as a PAH clinical trial end point. The mortality risk of an
elevated TRV and NT-pro-BNP level in SCD is limited to adults
$18 years of age. Additional studies are needed to accurately
define a composite model in the pediatric population. In 2014,
National Heart, Lung, and Blood Institute guidelines were unable to
make a recommendation for or against the use of echo alone as
a screening PH test for mortality due to insufficient evidence
(no comment on mortality).69 American Thoracic Society guidelines
in the same year recommended that adult SCD patients undergo
screening echocardiography and/or NT-pro-BNP testing to assess
the risk of having PH and of death for the purposes of diagnosis and
intensification of therapies while recognizing the absence of studies
on the use of hydroxyurea and chronic transfusions in placebo-
controlled trials in patients with SCD with PH.57
Diastolic dysfunction While “normal” ranges have not been
rigorously defined for diastolic function in SCD, diastolic dysfunc-
tion is present in #60% of patients using non-SCD population
as a reference.70-72 In the Walk-PHASST screening study, the
ratio of mitral peak velocity of early filling (E) to early diastolic
mitral annular velocity (e’), E/e9 was an independent predictor of
a shorter 6-minute walk distance.73 In the National Institutes of
Health PH screening study, diastolic dysfunction as reflected by
a low E/A ratio (which is the ratio of peak velocity flow in early to late
diastole caused by atrial contraction, the A wave) was associated
with excess mortality, even after adjustment for TRV.74 The presence
of both diastolic dysfunction and an elevated TRV conferred a risk
ratio for death of 12.0 (95% CI, 3.8-38.1; P , .001).74 The panel
determined that measurements of Doppler E/e9 and E/A are
surrogate markers of diastolic function in SCD while invasively
measured (via RHC) pulmonary artery wedge pressures are
one of several direct measures of diastolic function. Because of
associated mortality risk, further study is needed into the utility
of the E/A velocity ratio. Cardiac MRI utility to assess myocardial
fibrosis,73,74 while interesting mechanistically and clinically, is a future
target for clinical trials design as well. Clinical studies suggest utility
of these end points in pediatric and adult populations.
Exercise capacity The 6-minute walk test has been used in
adults and pediatrics to capture exercise capacity, as it predicts
mortality and response to treatment in a diverse group of lung
diseases.70,75,76 Both adult and pediatric patients with SCD can
have abnormal 6-minute walk test results, which may be associated
with anemia or low fetal hemoglobin (Hb) or cardiopulmonary
dysfunction.77,78 Mild-moderate dyspnea with exertion is extremely
common in SCD, occurring in 50% of HbSS and 40% of HbSC
adults.79 Cardiopulmonary disease has been associated with poor
exercise capacity in patients with SCD.74,80 The panel suggests
performing a 6-minute walk test as a direct end point for PAH,
using a change in distance walked (meters) as the outcome. In
PH, the minimal clinically important distance on this test is between
30 and 40 m; however, a minimally clinically important change has
not been established in SCD patients.77 The panel identified more
literature on cardiopulmonary outcomes in adults associated with
abnormal 6-minute walk test results.70,74,81 Therefore, the panel
recommends using the 6-minute walk test as an outcome in adult
SCD trials but recognizes that in the future, this may be expanded to
pediatric trials.82
ACS ACS is a frequent complication in both children and
adults living with SCD.71,72,83,84 Patients diagnosed with ACS
can deteriorate and it is a leading cause of disease-related
mortality for patients with SCD.5,85-89 Hydroxyurea can decrease
the incidence of ACS but does not eliminate the risk.83,90 Therefore,
additional novel therapeutic strategies should be evaluated, alone or
in combination with hydroxyurea, to further reduce the incidence
and prevent progression of disease. Direct end points for clinical trials
include (1) ACS using the currently accepted ACS definition83,84,91-93
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and (2) additional therapeutic interventions for ACS (eg, assisted
respiratory support, oxygen requirement, and/or RBC transfusion).84,94,95
C-reactive protein, sPLA2, thrombospondin-1, and pentraxin 3 are
possible biomarkers for predicting occurrence of ACS.
Asthma/reactive airway disease Asthma is a comorbid
factor in SCD.96-103 Studies confirm that asthma predisposes
to complications such as vaso-occlusive crises (VOCs),82,104-107
ACS,108,109 and stroke109 and is associated with increased
mortality.110,111 The panel recommends that studies use time to
first sickle cell event (pain or ACS) or change in incidence for
developing an event as direct end points in all ages.
Patients with SCD often have abnormal pulmonary function and
low forced expiratory volume in 1 second at baseline, so it would
be difficult to determine the meaning of this end point. However,
it may be considered an indirect end point, because it has been
demonstrated to be an independent predictor of early death in
adults with SCD.112,113 “Symptom-free days” (no wheeze, no
cough, no clinical need for albuterol, and no nighttime waking
from cough) is a commonly used end point in asthma studies
that may also be used in SCD.
Venous thromboembolism Clinical trial venous thromboem-
bolism (VTE) end points in patients with SCD do not need to differ
from other current thrombosis trials; guidance is available
regarding end points and outcomes measures.114 The panel
suggests trials that evaluate the percentage of patients that
develop pulmonary embolism or VTE as direct end points as well as
future research to assesses VTE prevention strategies and the risks
and benefits of sustained anticoagulation for VTE. Trials should
include all age groups, though the risk of VTE in children with SCD
may be primarily associated with indwelling catheters.115
End points for assessing therapies with
curative intent
Curative intent approaches involve hematopoietic stem cell (HSC)
transplant (HSCT), either using an unaffected donor or a donor with
sickle cell trait (allogeneic transplant) or autologous hematopoietic
stem and progenitor cells after gene modification (gene addition or
gene editing). A precise correlation between efficacy parameters
after allogeneic HSCT (eg, lineage-specific donor chimerism) or
autologous/gene therapy (eg, vector copy number [VCN], per-
centage of alleles with homology-directed repair, and homology-
directed repair edited) and outcome has not been standardized
between clinical trials as the pace of disease modification can be
variable depending on age, intervention, and disease burden. In
addition, treatment-related adverse effects need to be tracked and
taken into consideration in descriptions of the risk-benefit ratio.
Outcome measurements after transplant overlap with outcome
descriptions from organ-specific panels. To reach a common
goal of uniformity across trials, it is recommended that the end
points discussed below be measured and reported across all
HSCT studies in SCD. The panel recommends that data be
collected at least at 1-, 2-, 5-, 10-, 15-, and subsequently 5-year
intervals, even if the latter time points are through remote questionnaire
or phone. It is important that mechanisms be established for long-term
follow-up and for public reporting of these data. An overview
of outcomes tracking following curative therapy interventions
with suggestions regarding frequency of follow-up have been
published recently based on a consensus conference held by the
Pediatric Blood and Marrow Transplant Consortium.116
Biomarkers for therapies with curative intent
The effect of HSCT on the hematological expression of SCD has
been reported.117-121 End points that capture primary hemato-
logical markers of the disease (see "Hematological biomarkers"
and Table 3) must be obtained. These end points will not be
useful for assessing a curative outcome until a period of time
without concomitant medications and without disease-related
complications has elapsed. Posttransplant complications and
mortality, if present, should be tracked (eg, infections, graft-versus-
host disease [GVHD] or antierythrocyte antibodies).
Multiple technologic developments are needed for assays such as
F cells, where HbF is a potential therapeutic Hb. Improvements
and standardization for F-cell assays are needed as well as assays
to detect cellular distribution of antisickling Hb, such as T87Q
and AS3 Hb, and assays to measure the cellular distribution of
HbA/HbS.
Quantitative RBC physiology measures are needed to demon-
strate recovery from abnormal properties after therapy. These
assays may demonstrate the cellular impact of therapy on a critical
pathophysiologic molecular event. Rheologic assays that might
quantify hypoxia-induced rheologic changes in SCD and can
distinguish SCD from changes after HSCT or RBC transfusions
have been reported recently.122 For any of these assays, the
panel encourages using untreated SCD, SCD after transfusions,
and assays obtained after HSCT with healthy donor blood to
benchmark the assays.
Traditional laboratory biomarkers of SCD amelioration or cure in
HSCT clinical trials include those in Table 4, such as transfusion
requirements and VOCs, organ function, and PROs identified in
those specific sections. HSCT complications such as acute and
Table 3.Measures of normal or genetically corrected RBCs proposed
to assess for cure in SCD
End point Measures Grade of cure
Anemia and hemolysis Hb; reticulocyte counts;
normal Epo, sTfR, LDH,
haptoglobin, hemopexin; cell
free Hb; RBC microparticles
1: All parameters normal
2: Compensated anemia
(Hb near normal, high
reticulocyte counts,
sTFR, Epo)















cellular distribution of anti-








Epo, erythropoietin; HPLC, high-performance liquid chromatography; LDH, lactate
dehydrogenase; sTFR, soluble transferrin receptor.
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chronic GVHD, early and late graft rejection, immune constitution,
and impact on organ functions need to be collected as previously
described.116 Tracking the novel predictive biomarkers for acute
and chronic GVHD123 severity, which are beginning to emerge in
the allogeneic transplant setting, can be considered (Table 5).124
Gene therapy and gene editing
Despite the curative potential of HSCT, limitations and compli-
cations have led to development of transplantation of autologous
HSCs genetically corrected through both gene addition and editing.
These alternative approaches are targeted to patients for whom a
medically suitable donor is not available or the risk of an unmodified
HSCT is unacceptably high.125,126 Determinants of successful gene
therapy and editing will include (1) adequate HSCT dose of gene-
modified CD341 cells and the ability to accurately ascertain the
CD341 subpopulation of gene-targeted HSCs, (2) adequate stable
engraftment of gene-modified HSC’s and chimerism to ensure
phenotype-ameliorating increases in HbA or HbF, and (3) optimiza-
tion of recipient BM niche to enable adequate engraftment. Current
laboratory and clinical biomarkers of successful amelioration of
the SCD phenotype in the design of gene therapy/editing would
be similar to those outlined for HSCT (Table 4). The primary
safety concerns if additive gene therapy using viral vectors will
remain off-target insertional mutagenesis and transgene silenc-
ing, and the development of appropriate biomarkers to identify
and monitor these effects will be critical (Table 6).125 With gene
editing, further advances in methods for high-fidelity sequencing
and genome-wide assessment of off-target cutting, off-target integra-
tions of the homology donor template, and effects on genome integrity,
including chromosomal translocations in primary human hematopoietic
stem and progenitor cells, will be required to more precisely identify
and interrogate nuclease-specific off-target mutagenesis.
The laboratory biomarker panels and clinical outcome parameters
assess the success of SCD curative therapies aim to measure
the amelioration of the overt SCD phenotype. They do not measure
several important underlying biochemical, metabolic, and transcrip-
tomic determinants of SCD pathophysiology such as endothelial cell
activation and microvascular flow, ischemia and reperfusion, tissue
oxygenation, and perturbations in the SCD patient’s epigenome,
proteome, and metabolome (Table 7). Understanding these and
other underlying mechanisms will permit deeper phenotyping of the
SCD patient and better inform the short- and long-term phenotypic
impact of the type/timing of the various curative SCD strategies.
While the hallmark of a successful outcome after allogeneic
HSCT for SCD is the full replacement of recipient HSCs in the
marrow by healthy donor HSCs, termed full donor engraftment,
this is not necessary for a curative outcome. The observation of
stable mixed hematopoietic chimerism after HSCT for thalas-
semia and SCD demonstrated that even a minority of donor cells
that have stable engraftment are sufficient for eliminating anemia,
hemolysis, and the clinical symptoms of SCD.119-125 Because the
donor chimerism threshold sufficient for a curative effect is uncertain
and influenced by a number of host factors such as the genetic
makeup of the donor (unaffected or with trait) more research is
needed for these end points (percent chimerism and HbS level).
Current data from mixed chimerism following HSCT suggests
that a percentage of normal donor chimerism may correct the
disease and the degree of chimerism may be dependent on the
sickle RBC half-life.117,126,127,128 Currently, data are lacking for
the degree of chimerism of gene-modified grafts that correct
the clinical phenotype and the laboratory parameters. However,
engraftment in the range of 20% for erythroid or myeloid chimerism
and an HbS level ,50% with transfusion support has been
suggested.127,128
For any genetic modification or stem cell transplant approach,
morbidity and mortality from conditioning, including acute and
long-term and durability of the efficacy outcomes, should be
monitored and reported. Data on long-term side effects such as
second malignancies, endocrine effects, and effects on fertility
hormones, fertility, growth, and development should be col-
lected. Clonal diversity may also be a correlate for efficacy and
safety. Increasing evidence shows that clonal hematopoiesis is
common after HSCT, with outcomes ranging from clinically si-
lent oligoclonal hematopoiesis to myelodysplasia or leukemia.129
Assessment methods for clonality may provide useful infor-
mation regarding the long-term effects and could provide an
Table 4. Laboratory and clinical biomarkers proposed for therapeutic
monitoring
Therapeutic monitoring










Increase in HbF (a2g2) GT/E Surrogate Strong





Change in VOC SCT/GT/E Direct Intermediate*
Change in all pain levels SCT/GT/E Direct Intermediate*




GT/E, gene therapy/editing; SCT, stem cell therapy.
*Could be strengthened by choosing targets that meet the FDA guidance for rare
disease trial end points (https://www.fda.gov/NewsEvents/Newsroom/PressAnnounce-
ments/ucm613026.html).
Table 5. Laboratory and clinical biomarkers for adverse event
monitoring
Adverse event










Off-target mutagenesis GT/E Possibly predictive Strong
Clinical biomarkers
Early vs late graft rejection SCT Direct Intermediate
Alloantibody development SCT Direct Intermediate
Acute vs chronic GVHD
biomarker panels
SCT Surrogate Research gap
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early warning for complications (eg, onset of aplasia or progression
to myelodysplasia).
The analysis and reporting of off-target modifications and effects on
genome integrity after genomic editing is important, but standard-
ization of this end point is not yet possible. The end point will be
better defined as the clinical translation experience expands with
better algorithms to design gene editing tool sets.
Clinical toxicity end points The incidence and severity of
GVHD in the acute and chronic forms must be recorded and
included in outcome measurements after allogeneic HSCT.
There are standardized methods for documenting and reporting
GVHD that should be followed.130 Similarly, duration of immune
suppression/modulation and its side effects (infection incidence)
and immune reconstitution/response to immunization (postimmuni-
zation titers) should be recorded.
Clinical end points are necessary to document the influence of the
treatment modality on the manifestations of the disease as it relates
to organ functions. Change in organ function after treatment is
expected to vary with the age at which the treatment (stem cell
transplant or autologous genetically modified cell infusion) is
undertaken. Established organ damage is not expected to
recover back to a baseline normal.24,131,132 Permanent organ
function impairment is likely in older patients and those with
severe disease manifestations and may have predictive geno-
typic, phenotypic, or biochemical biomarkers. However, these
are not established and remain speculative at the current time.
In many patients, the clinical benefits of intervention may have to
be “graded” to measure benefit as opposed to an expectation of
return to normalcy. In certain situations, the intervention may be
deemed beneficial in the absence of further deterioration as would
be expected with the natural history of the disease. The Panel on
Measurement of Cure recommends that organ function baselines
be established before treatment and continue to be tracked 1, 2,
5, 10, and 15 years following intervention.
Gonadal function and fertility preservation The age at
which curative treatment is undertaken and exposure to toxicities
of conditioning therapy can influence gonadal outcomes. Two
forms of gonadal insufficiency can occur after myeloablative therapy
in childhood: hypogonadotropic hypogonadism due to pituitary
iron overload and hypergonadotropic hypogonadism due to gonadal
damage from conditioning chemotherapy. Hormonal function
in prepubertal boys is usually better preserved than fertility, as
Leydig cells are less sensitive to conditioning agents than
spermatogonial cells. Hormonal function and fertility are equally
impaired in prepubertal girls, and ovarian insufficiency is very
common following HCT after puberty, particularly after exposure
to myeloablative busulfan. Reduced-intensity conditioning has
shown preservation of hormonal function and/or fertility in some of
females, although further evidence on effects on male fertility is
needed. Baseline gonadal function (Tanner staging and gonad-
otropin and hormone levels) should be assessed in all patients
$11 years of age before myeloablation if a busulfan-based or
other alklyator therapy is used. Following the curative therapy,
annual assessments of pubertal development, sexual, and repro-
ductive function is recommended based on accelerated impairment
following exposure to conditioning regimens. This includes luteiniz-
ing hormone, follicle-stimulating hormone, anti-Mullerian hormone,
and estradiol levels in females and follicle-stimulating hormone,
luteinizing hormone, and early morning testosterone levels in males
when recipients are $11 years of age.
Liver Liver function can be affected by prior vaso-occlusive
infarction, iron deposition caused by chronic transfusion therapy,
and conditioning therapy such as busulfan. Liver iron content can
Table 6. Potential biomarkers for postcurative monitoring
Therapeutic monitoring







Change in deep tissue oxygenation
steady state* (SpO2, pCO2, pO2;
bicarbonate, lactate; VO2; VCO2)
SCT/GT/E Surrogate/direct Research gap
Steady-state ischemia/reperfusion*
(TNF, NF-kB, IL-b1; WBC
adhesion)
SCT/GT/E Surrogate/direct Research gap
Change in endothelial activation*
(P-selectin expression)
SCT/GT/E Surrogate/direct Research gap
Change in proteomics/epigenetics/
metabolomics*
SCT/GT/E Surrogate/direct Research gap
IL, interleukin; TNF, tumor necrosis factor.
*Potential biomarkers that meet the FDA guidance for rare disease trial end points
(https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm613026.htm).
Table 7. Quantification/surrogates of engrafted corrected HSCs proposed for use in measuring cure in SCD
End point Measures Grade of Cure
GT/E VCN or edited cells and alleles in infusion product and 0.5, 1, 2, 5,
10, and 15 y after genetic modification (%); genetically modified
and allele modified CFUc (%)
VCN in infused product and up to 6 mo after GT/E can be higher;
stable VCN (at year 1 onward) that results in:
1: 100% genetically corrected RBCs
2: 75%-100% corrected RBCs
3: 50%-75% corrected RBCs
4: 25%-50% corrected RBCs
5: 0%-25% corrected RBCs.
Corrected RBCs may be defined as antisickling Hb containing
RBCs and/or RBCs that resist sickling (%)
Engraftment Normal or genetically modified HSC chimerism (%) 1: .50%
2: .20%
CFUc, colony-forming units in culture.
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be assessed by T2* MRI scans. A liver biopsy in patients who
have long-term transfusion exposure might be useful to identify
hepatic fibrosis and the risk of cirrhosis after treatment.
Specific clinical end points of cure related to
SCD phenotype
Pain/VOCs Tracking the frequency and severity of VOCs in
the manner previously described (hospitalization and opioid use)
is important after curative therapy interventions to determine the
effects of the therapy on this important component of the disease.
PROs can be determined with patient and caregiver input using
validated measures as previously described.2
Cardiovascular and pulmonary end points Although the
change in markers of cardiovascular and pulmonary function would
be predicted to change slowly over time, resolution of an underlying
abnormality is not generally observed. Thus, these end points might
be used to establish stability of function after the curative therapy.
(See “End-organ diseases: renal and cardiopulmonary end points in
SCD” for further details.)
Neurological end points Neurological end points are provided
by the brain panel and are discussed in detail in “ End points for
assessing brain outcomes in SCD" of the companion end point
paper by Farrell et al.2
CKD end points As noted for other end organs, end point
stabilization in lieu of improvement is expected (see “Renal end
points” for further details).
Assessment of PROs
PRO assessments following a curative therapy are valuable for
complex decision making. They quantify broad non–organ-specific
impacts of a disease-free state and are influenced by transplant
complications such as chronic GVHD. Assessments before HCT
and at 6 months, 12 months, 2 years, and yearly beyond if indicated
can provide global functional outcomes.2 Detailed information on
PRO assessments as clinical trial end points are provided in the
PRO section of the companion end point paper by Farrell et al.2
In summary, the panel recommends long-term multifaceted outcome
assessment and analysis following curative therapies as applicable,
including (1) disease-related complications related to SCD pheno-
type; (2) disease-related organ functions; (3) transplant-related
complications; (4) generalized psychosocial performance, societal
integration, and health-related quality of life (PRO); and (5) impact of
cure-directed interventions such as genetic manipulation.
Summary: defining the degree of “cure”
After an allogeneic transplant when there is full “healthy” donor
chimerism, a cure from SCD can be obtained; however, these
patients still need to be assessed for acute and late adverse
event end points. Partial chimerism is likely after gene transfer or
gene editing and autologous transplantation, where the fraction
of genetically modified or edited HSCs that engraft a patient will
vary (depending on gene transfer/gene editing efficiency, HSC
dose, conditioning regimen). Hence, there will be varying amount
of chimerism of corrected versus disease HSCs. In this setting,
the degree of cure may also vary.
A “scorecard” for judging the effect of the curative therapy
becomes imperative when so many different curative options are
in trials or in preparation. A graded end-point system will allow
comparisons of different vectors, conditioning regimens, gene
editing modalities, and transplant regimens, as well as the toxicities
associated with each, so that providers and patients can make an
informed decision and chose a curative modality that is acceptable,
feasible, and safe for a particular individual.
The curative end points and associated toxicities could be graded.
An initial grading proposal is suggested in Table 8, which could be
refined iteratively as data become available. PROs could be
integrated into this grading system.
Adherence end points
The biomarkers panel stratified adherence biomarkers for clinically
indicated medical therapies in SCD based on those viewed as
clinically validated and in wide use in children and adults. While
much of the data and measures evaluate hydroxyurea use, many
of the markers may be partly applicable for evaluating adherence
to other treatments (eg, immunosuppressive agents posttransplant).
These include blood cell standard clinical measurements133-135;
increased mean corpuscular volume (MCV; uncertain physiological
benefit vs marker of hydroxyurea effect); reduced white blood
cell (WBC) count (useful for reduced inflammation, cytokine
production, and endothelial/cellular activation through receptor
activation); reduced platelets (similar to WBCs); HbF levels
(percentage or absolute amount, average untreated HbF)133,135
and Hb above the median (“Hb augmentation,” the benefit of
which is improved physiology through suggestive markers such
as energy and oxygen flow); and markers of hemolysis, which
reflect improved RBC stabilization (lower reticulocytes by absolute
reticulocyte count,133 reduced LDH to more normal levels, and
reduced indirect bilirubin). Physiological biomarkers that are
useful in young children but are poorly quantitative (except over
the long term) include growth curve in young children,136,137
and early splenomegaly.5
Promising but not rigorously validated biomarkers include (and
are not limited to): sickle RBC rheology (from whole blood138 or
microfluidic122); RBC ektacytometry138; oxygen affinity by whole
blood oximetry139 (eg, reduced 2,3 DPG140); in vitro sickling (by
bright field microscopy141); microparticles (derived from PRB,
platelets, and/or monocytes142); and proteomic markers of cellular
activation or sickle pathology.
Widespread poor adherence for therapeutic hydroxyurea in
SCD has been documented by pharmacy refill databases and by
reduction from peak HbF levels, a sensitive biomarker for dose-
dependent hydroxyurea use. A validated measure for adherence
is the highest historical hydroxyurea-induced HbF as a minimum
target for an individualized personal best self-management goal.143,144
For that reason, a personalized biomarker, “personal-best HbF,”
can add to other adherence measures employed, both biological
(eg, MCV, Hb, and absolute reticulocyte count) and pharmacy refill
data.143 Most studies use more than one method to assess medica-
tion adherence, often a physiological and another.145 Importantly, while
self-reporting is consistently the weakest marker of adherence,
many studies continue to use self-reported adherence,146 often
using a version of a “Moritsy” scale,147 which is not recommended.
Hematological biomarkers Hematological biomarkers can be
divided as either “pure” characteristics of hematological mani-
festations in SCD, such as severity in anemia or hemolysis, or as
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characteristics that refer to changes in other extrahematological
organ systems (such as creatinine or GFR) but found in the circulation.
Pure hematological biomarkers include blood cell standard clinical
measurements133-135; Hb above the median (Hb augmentation, the
benefit of which is improved physiology through better energy [soft]
and oxygen flow [soft]); increased MCV as a marker of hydroxyurea
effect; reduced WBC (a useful marker of reduced inflammation,
cytokine production, and endothelial/cellular activation through
receptor activation); reduced platelets (sudden decrease in platelet
counts is often a marker of increase severity and impending
worsening of ACS or multiorgan failure); HbF levels (percentage
or absolute amount, average untreated HbF, intracellular concen-
tration, and distribution)133,135; and markers of hemolysis, which
reflect improved RBC stabilization (lower reticulocytes by absolute
reticulocyte count,133 reduced LDH to more normal levels, and
reduced indirect bilirubin and aspartate aminotransferase).
The bone marrow (BM) and the BM niche can be seen as an organ
in itself, with potential for progressive end-organ damage, for which
no marker has been suggested to date in SCD. In contrast, the
process of BM aging in the general population has been well
described, and markers such as mean telomerase length and
genes such as DNMT3A, TET2, or ASXL1148 have been reported.
Such markers could be relevant in SCD as patient age increases
and the BM environment is exposed to stressors (eg, hydroxy-
urea). Conventional biomarkers, such as Hb, WBC, platelets and
platelet activation markers, plasma free Hb, reticulocyte count,
Hb F percentage, and a thalassemia have all been reported within
specific complications such as stroke, leg ulcers, priapism, and
VOCs. Ferritin has been found to be a marker of early mortality in
several case series, reflecting a probable biomarker of severe
disease and inflammation/oxidative stress.149 WBC transcrip-
tomes and microRNAs are newcomers to this field and deserve
more rigorous scrutiny. Rheology assessment with microflui-
dics, as mentioned earlier, offers the promise to measure blood
flow and is especially useful when evaluating a single patient under
different clinical conditions. These assessments can be done in
an endothelialized system or looking at P selectin without the
endothelial lining.
Hb is a useful clinical end point, and degree of anemia has been
correlated with higher transcranial Doppler velocities, increased
risk of stroke, renal and cardiopulmonary complications, priap-
ism, leg ulcers, and cognitive dysfunction. While composite end
points such as the hemolytic index have been validated as indicators
of hemolysis and have been associated with certain complications,
they need further studies for prognostic validation and clinical
applications (ie, changes in the hemolytic index leading to improved
survival or reduced complications). Markers of inflammation, such
as C-reactive protein and erythrocyte sedimentation rate, which
are not strictly hematological markers, may have value in assessing
hematological response to a therapeutic intervention that targets
the inflammatory pathway.
End points for trials in low-resource settings
An estimated 300 000 affected children born every year in
sub-Saharan Africa (SSA), representing 80% of the global
burden of SCD.150 Approval of existing therapies for SCD have
been based on clinical trials conducted in high-resource settings.
Advantages of conducting trials in low-resource settings can include
rapid enrollment, answering questions on disease heterogene-
ity, disparate outcomes in individuals of similar phenotypes, and
uncovering the natural history of SCD and its specific complications
in addition to a resource for experimental clinical trials. SCD clinical
trials with primary and secondary outcome measures conducted in
high- and low-resource settings often differ in their intent, with trials in
low-resource settings more focused on dosing, effectiveness, and
optimizing or expanding existing treatments than on testing new drugs.
The main drivers of SCD-related outcomes in individuals living in
low-resource settings include early childhood mortality (,5 years
old),151 perioperative mortality,152,153 and poor pregnancy-related
outcomes (increased maternal and perinatal mortality).154 Based on
the disparate disease-related outcomes of individuals with SCD in
high- vs low-resource settings, research studies must develop
relevant clinical end points that take into consideration unique
factors that determine disease-related outcomes applicable to each
region that are pivotal for investigating SCD biology, phenotypes,
and new therapies.
Table 8. Potential grading schema for pain and patient-reported quality-of-life outcomes after curative therapy
End point Measures Grade of cure
Pain Pain events; ain events requiring hospitalization; oral pain
medications (narcotics and NSAIDs) per month and per year;
parenteral opiate use per month and per year





Patient-reported quality-of-life outcomes Pain, affect functionality; PROMIS; ASCQ-ME; PedsQL; PHENX
toolkit; HPQ; SCSES; COPM






ASCQ-ME, Adult Sickle Cell Quality of Life Measurement Information System; CPOM, Composite Functional Outcome; HPQ, Health and Work Performance questionnaire; NSAID,
nonsteroidal anti-inflammatory drugs; PedsQL, Pediatric Quality of Life Inventory; PHENX, phenotypes and exposures; PROMIS, Patient-Reported Outcomes Measurement Information
System; SCSES, Sickle Cell Self-Efficacy Scale.
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Implications for clinical trials design
Health care delivery systems in SSA have implications for clinical
trial design and focus (safety, dosing and effectiveness, lifesaving
interventions, and primary vs secondary prevention). Most individ-
uals with SCD in SSA do not have access to comprehensive care,
and research outcomes from comprehensive care centers in urban
areas may not be applicable to the rural settings where individuals
have limited access to SCD care. Individuals with SCD living in rural
areas who must travel long distances to SCD centers would face
challenges with regular visits for tests and clinical examinations
mandated by study requirements.
Further, the nutritional status of patients may pose challenges with
dosing and bioavailability of therapeutic agents. Children with
SCD, similar to children with other chronic diseases, are at risk
for delayed growth and pubertal maturity,155-157 which may be
exacerbated in the low socioeconomic environment of low-resource
settings. This could result in exclusion of patients with very low z-scores
based on body mass index measurements,158 leaving questions
about application to malnourished/stunted patients unanswerable.
Clinical trial design process should involve practitioners managing
individuals with SCD in SSA. Their local expertise and insights are
crucial in contextualizing research design to achieve the aims and
objectives. Safety reporting in SSA could be variable depending on
the skillset and experience of research coordinators.
Meaningful PROs that are context specific for SSA communities
are needed as end points. For example, growth and development
are more meaningful in the region. In addition, assessment of
physical activity and school attendance as a measure of health-
related quality of life (HRQoL) among patients in the United
States or Europe may not be as meaningful or applicable in SSA.
Neuropsychological assessments would have to consider cultural
sensitivities, including language barriers, and tools for assess-
ments would have to align with what has been validated for use
in clinical practice. End points that rely on hospitalization or
utilization of health facilities would not be reliable in the SSA
context, where resource constraints place barriers to utilization
of health-care resources.
Overt stroke as an end point is feasible in SSA, as validated tools for
stroke diagnosis based on neurological examination are feasible.
However, resources for MRI are limited in SSA. Silent stroke,
the diagnosis of which is imaging dependent, would not be
feasible; however, neurocognitive assessment, a surrogate end
point of SCD-related cerebrovascular disease, is possible using
validated tools if adapted to the SSA setting. Where measur-
able biomarkers are needed as end points, the equipment and
methodology for such measures need to be monitored to ensure
accuracy of such measurements. Ease of safety reporting could
also be variable depending on the skills and experience of research
coordinators.
Reducing SCD mortality in low-resource settings
SCD is associated with a very high rate of childhood mortality at
50% to 90% in SSA.159,160 The Garki study provided valuable
information on childhood survival and other aspects of the natural
history of SCD, although current information on the burden of
mortality from SCD in Africa among populations based on
access to currently available treatments and preventive inter-
ventions is lacking.161 In Tanzania, 10 313 children with SCD
,5 years of age are estimated to die every year, an estimated
7% of overall deaths in children ,5 years.162
In a prospective study evaluating posthospital mortality in children
aged 2 to 12 years, SCD alone accounted for 21% (10/47) of
the deaths in the first year after hospital discharge.163 Attribut-
able factors included severe malnutrition, neurologic diseases,
heart disease, cancer, and septic shock. Other risk factors
significantly associated with mortality included older age, lower
Hb level, lower Glasgow Coma Scale, history of decreased urine
output, higher respiratory rate, estimated GFR,60 mL/min/1.73 m2
(binary), and lower oxygen saturation. These determinants of
outcome are risk factors that frequently complicate SCD, especially
in low-resource settings, with implications for clinical trial design
and feasible end points.
Though there has been increased childhood survival for patients
with SCD in high-income countries, early mortality in young adulthood
is still the norm.1 Individuals in low-income settings who survive to
adulthood face the challenge of living with a chronic morbidities
requires comprehensive care in a region where this does not exist.
The median survival for men and women with SCD remains dismally
low, at ;42 and 48 years, respectively, in high-income settings but
remains unknown in low-resource settings.87 Understanding the
patterns of morbidity, mortality, HRQoL, and health care utilization in
individuals with SCD living in low-resource settings will be relevant
in designing clinical trials with clinical trial end points that are impactful
in these settings.164-166 Table 9 summarizes suggested clinic trial
end points that focus on reducing mortality in low-resource settings.
Age and organ-specific SCD morbidity and mortality:
relevance for clinical trial end point considerations in
low-resource settings
Patients with SCD are at high risk for age-dependent morbidity
and mortality from end-organ complications. While strokes, infec-
tion and organ sequestration are the leading causes of death in
childhood, chronic organ failure, including CKD and cardiopul-
monary disease become two of the most common causes of
death or findings at the time of death in adults with SCD.4-6
Increased childhood survival has also resulted in more females
with SCD reaching reproductive age in low-resource settings,
with poor pregnancy-related outcomes (increased maternal and
perinatal mortality).154 SCD-related chronic impairment in multiple
organs and its association with mortality167 highlight the need to
understand the common mechanisms underlying chronic end-organ
damage in SCD. In low-resource settings, there is an urgent
need to develop simple interventions to prevent irreversible end-organ
complications and poor pregnancy-related outcomes associated
with SCD. Table 9 summarizes clinical trial end points appropriate
for low-resource settings for PH, ACS, CKD, and primary and
secondary stroke prevention, recognizing that traditional end
points might not be feasible or pragmatic in these settings.
Therapeutic trials: relevant clinic trial end points in
low-resource settings
Multiple ongoing clinical trials are investigating the use of novel
agents in SCD.168 A review of the website www.clinicaltrials.
gov reveals approximately .30 agents that are presently
being tested in SCD, mainly in high-resource countries. These
drugs include HbF inducers, anti-oxidants, antiadhesive agents,
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anti-inflammatory agents, antisickling agents that modify Hb
oxygen affinity, anticoagulants, and antiplatelet agents. To improve
generalizability, some of these trials need to be conducted in low-
resource settings. In addition to traditional clinical trial end points
such as the evaluation of acute pain crisis, other surrogate end
points such as SCD-related end-organ complications, exercise
capacity, and locally applicable PROs in low-resource settings
should be introduced. These are warranted and necessary in order
to advance the development of these novel therapeutic agents.
Table 10 reviews traditional clinical trial end points and suggested
modifications in low-resource settings.
Summary: clinical trial end points for
low-resource settings
The renewed focus on SCD specific clinical trials in SSA is long
overdue. Identifying appropriate clinical trials with interventions that
could affect the disparate mortality of affected individuals in low-
resource settings are urgently needed. A renewed focus is needed
on clinical trial designs with end points for primary (such as primary
stroke prevention), secondary (such as secondary stroke prevention
or reducing progression of CKD), and tertiary prevention (improving
quality of life, symptom reduction, and disease amelioration) that
can be implemented within existing health care frameworks in
specific low-resource settings.8 Early identification of affected
children through establishment of newborn screening programs,
point-of-care testing, and capacity building for laboratory diagnosis
of SCD, coupled with SCD comprehensive care programs, will help
set the stage for opportunities for prospective studies with relevant
clinical trial end points in these settings.
The large population of affected individuals in low-resource settings
provides opportunities to improve the understanding of dis-
ease heterogeneity, disparate outcomes in individuals of similar
Table 9. Clinical trial end points focused on reducing mortality and morbidity in SCD in low-resource settings
Research focus Attributable risk factors Clinical trial end points for low-resource settings
Reducing mortality in SCD in low-
resource settings
Reducing ,5-y-old mortality Unknown natural history of SCD in SSA; infections (malaria and
invasive bacteria); splenic sequestration and severe anemia;
severe malnutrition and diarrheal illnesses
Newborn screening programs to better estimate number of
patients affected, survival, and complication rates. This
needs to be coupled with comprehensive care programs.
Estimate impact of antimalarial prophylaxis; vaccination for
common bacterial infections and penicillin prophylaxis until
at least 5 y; and improved nutrition, and interventions against
diarrheal illnesses.
Reducing pregnancy-associated mortality Increased risks of both SCD-specific and pregnancy-related
complications (maternal death rate of SCD is 7%-12%)
Multidisciplinary interventions to reduce and manage
hypertensive disorders of pregnancy (preeclampsia,
eclampsia), severe anemia and urinary tract infections,
antenatal and postnatal-acute pain episodes, and
pregnancy-associated VTE
Reducing perioperative mortality Poor transfusion practices; perioperative supportive care;
postoperative infections
Reducing risk of transmission of transfusion associated
infections; local interventions to reduce ACS postoperative
complications; reduction in postoperative VTE
Organ-specific clinic trial end points in
low-resource setting
PH Composite model: TRV .2.5 m/s and either NT-pro-BNP
$160 pg/mL or 6-min ,330 m
Mortality from PH exercise capacity (6-min walk test; change in
distance walked)
ACS Define ACS based on current accepted definition (definition of
a new pulmonary infiltrate (excluding atelectasis) and chest pain,
fever, tachypnea, wheezing, or cough
Percentage of patients who develop ACS based on modified
criteria and adjudicated
CKD Severe albuminuria (.300 mg/g); moderate albuminuria
(30-300 mg/g); CKD (stage .3 by GFR; stage .1)
Urine albumin/creatinine (% decrease in proteinuria);
measured or estimated GFR (percentage of patients who
require initiation of renal replacement therapy); progression
in stage of CKD
Primary stroke prevention Increased risk of stroke in children in low-resource setting (10%-
11%); increased incidence of causes of severe anemia (malaria,
iron deficiency anemia, severe malnutrition)
Reduction in TCD velocity in children; clinical and imaging
evidence of new stroke, TIA, or death; neurocognitive
testing, locally adapted Pediatric NIH Stroke Scale
Secondary stroke prevention Increased risk of stroke in children in low-resource settings
(10%-11%); increased incidence of causes of severe anemia
(malaria, iron deficiency anemia, severe malnutrition); lack of and
availability of safe transfusion practices; unavailability of disease-
modifying therapy (hydroxyurea)
Prevalence of recurrent stroke: NIH stroke scale
(questionnaire); clinical and imaging evidence of recurrent
stroke, TIA, or death; neurocognitive testing (NIH scale)
Therapeutic trials: relevant clinic trial
end points in low-resource settings
Phase 2 study of novel agents Pharmacokinetics and pharmacodynamics studies; safety and
efficacy of new agents; effect on splenic and renal function;
biological and hematologic correlates (HbF level, reduction of
intracellular Hb concentration, increasing nitrous oxide
bioavailability); antiplatelet, anti-inflammatory, anticoagulation,
and antiadhesion properties
Improvement in baseline Hgb, acute pain episodes rate,
hematologic toxicities or serious adverse events, biological
and hematologic correlates, other clinical end points: ACS,
ischemic stroke, CKD, priapism, PH, leg ulcers, avascular
necrosis
NIH, National Institutes of Health; TCD, transcranial Doppler; TIA, transient ischemic attack.
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phenotypes, and uncovering of the natural history of SCD and its
specific complications. In addition, this presents unique oppor-
tunities to help validate the efficacy of approved therapies, using
larger patient cohorts. To succeed, ongoing research needs to
establish a foundation of evidence within SSA, which involves
establishing international research partnerships and capacity
building, while simultaneously strengthening local SCD knowl-
edge, clinical experience, and care delivery.169
Conclusions
Patients with SCD have significant complications due to complex
pathophysiology. Identifying optimal end points for current use and
future development was the goal of the ASH-FDA Sickle Cell
Disease Clinical Endpoints Workshop. This report, along with the
companion report, noted where data exist to support including
clinical trial end points as a direct benefit, surrogate, or biomarker.
In addition, the report identifies where future work is needed
to develop additional end points in SCD. The results of this
work provide an exhaustive list of suggested direct end points,
surrogate end points, and biomarkers, along with future develop-
ment recommendations. As with any recommendation, the exact
clinical context must be considered before clinical trial end point
adoption.
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Table 10. Traditional clinical trial end points and suggested modifications in low-resource settings
Disease-related factors Traditional clinical end points Clinical end points for low-resource settings
Recurrent pain episodes Proportion of days with symptom exacerbation (SCDSM);
annualized sickle cell crisis rate; annualized VOC events
(number and length of hospital/ER visits, phone diary, home-
health visits over time); time to first pain crisis; duration and
severity of pain crisis
Electronic daily pain diary, phone tracking, plus hospitalization and
emergency room visit rate; reduction in average visual analog score
for pain
Disease amelioration Measuring HRQoL; increase in Hb .1 g/dL from baseline;
hemolysis biomarkers (total bilirubin, LDH, reticulocyte, total
WBC, platelet count, CRP, plasma D-dimers laboratory
values); frequency of SCD- related complications (VOC,
ACS, hepatic and splenic sequestration, leg ulcers, priapism
and stroke); changes in functional exercise capacity (6-min
walk test)
Increase in baseline Hb.1 g/dL; decrease in frequency of SCD-related
complications; changes in functional exercise capacity (6-min walk
test); improved growth in children; locally relevant PROs
Hematologic responses Increase in baseline Hb by 2 points; improvement in HbF from
baseline
Increase in baseline Hb by 2 points, quite feasible; improvement in HbF
from baseline, dependent on availability of HPLC machines, limits to
tertiary centers
PROs Symptom relief or HRQoL (multidimensional), including
physical, functional, social, emotional, and spiritual QoL, as
measured by QoL instruments
Lack of context-specific and culturally specific instruments that have
demonstrated validity, reliability, and sensitivity to clinically important
changes
CRP, C-reactive protein; QoL, quality of life.
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